Sucampo and Takeda may not be the first to launch a DTC campaign for a chronic idiopathic constipation (CIC) treatment. But the team, which markets Amitiza, is doing things a little differently.
Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while adding up to $400 million each--$1.6 billion in total--in fresh milestones.
Takeda Pharmaceutical has stepped up with a $25 million investment in Cleveland's BioMotiv, buying into the accelerator's promise to transform academic discoveries into market-bound therapeutics.
As promised, newcomer COO Christophe Weber is shaking things up at Takeda Pharmaceutical, with the Japanese company this week rolling out a revamped organizational structure that it hopes will make it the "best-in-class company in every aspect" of its business. And that includes vaccines.
Analysts have been waiting--and waiting--for drugmakers to realize the growth they've predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could finally be on the way.
With Contrave, Takeda is trying to go where no new-age weight-loss drugmakers have gone before. That means achieving the ultimate marketing goal of getting physicians to back its therapy, patients to stick with it and payers to cover it. And to help it take a shot at that trifecta, it's putting a force of 900 reps behind the drug.
Takeda didn't bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up. And now, as promised, the blueprints for a new, reorganized company structure are here.
Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.
Legal experts have insisted there is no way that a $9 billion punitive damage award against Takeda Pharmaceutical and Eli Lilly for hiding Actos risks can stand. But the two companies are still sweating that one out after a federal judge refused to throw out the verdict and its mammoth award on Thursday.
The dengue vaccine market may not exist yet, but once it does, it's in for a big growth spurt within the next 6 years, a recent report says. And while market watchers expect Sanofi's candidate to lead the pack, by the time 2020 rolls around, Takeda could be right behind it in the battle for market share.